MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI)
Conferences
Naseem, N; Badii, M; Agashe, S; Shroff, S
Published in: MUSCLE & NERVE
October 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
MUSCLE & NERVE
EISSN
1097-4598
ISSN
0148-639X
Publication Date
October 2020
Volume
62
Start / End Page
S70 / S70
Related Subject Headings
- Neurology & Neurosurgery
- 32 Biomedical and clinical sciences
- 31 Biological sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Naseem, N., Badii, M., Agashe, S., & Shroff, S. (2020). MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI). In MUSCLE & NERVE (Vol. 62, pp. S70–S70).
Naseem, Nishath, Melody Badii, Shruti Agashe, and Sheetal Shroff. “MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI).” In MUSCLE & NERVE, 62:S70–S70, 2020.
Naseem N, Badii M, Agashe S, Shroff S. MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI). In: MUSCLE & NERVE. 2020. p. S70–S70.
Naseem, Nishath, et al. “MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI).” MUSCLE & NERVE, vol. 62, 2020, pp. S70–S70.
Naseem N, Badii M, Agashe S, Shroff S. MILLER FISHER SYNDROME AS A CONSEQUENCE OF TREATMENT WITH IMMUNE CHECKPOINT INHIBITOR (ICI). MUSCLE & NERVE. 2020. p. S70–S70.
Published In
MUSCLE & NERVE
EISSN
1097-4598
ISSN
0148-639X
Publication Date
October 2020
Volume
62
Start / End Page
S70 / S70
Related Subject Headings
- Neurology & Neurosurgery
- 32 Biomedical and clinical sciences
- 31 Biological sciences